Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.37 +1.0%	$0.38	$0.24 ▼ $2.53	$21.38M	0.9	691,113 shs	346,634 shs
CMMB Chemomab Therapeutics	$0.93 +3.6%	$1.12	$0.87 ▼ $2.55	$16.92M	0.52	126,506 shs	124,827 shs
ENSC Ensysce Biosciences	$2.05 -0.5%	$2.16	$1.62 ▼ $14.67	$6.11M	1	884,406 shs	112,417 shs
PASG Passage Bio	$6.95 -8.4%	$7.07	$5.12 ▼ $26.60	$24.13M	1.81	83,615 shs	61,740 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	+0.99%	+4.25%	-4.49%	-8.12%	-78.11%
CMMB Chemomab Therapeutics	+3.64%	-4.11%	-18.42%	-32.12%	-11.43%
ENSC Ensysce Biosciences	-0.49%	-5.96%	-5.09%	-12.39%	-64.96%
PASG Passage Bio	-8.43%	+10.85%	+25.00%	+15.07%	-53.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	2.3292 of 5 stars	3.0	3.0	1.6	2.5	0.6
CMMB Chemomab Therapeutics	3.4671 of 5 stars	3.5	5.0	3.1	1.7	0.6
ENSC Ensysce Biosciences	0.6358 of 5 stars	0.0	4.0	3.2	0.0	0.0
PASG Passage Bio	3.7952 of 5 stars	3.5	5.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.00	Hold	$5.00	1,259.80% Upside
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	813.98% Upside
ENSC Ensysce Biosciences	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$91.75	1,220.14% Upside

Current Analyst Ratings Breakdown

Latest ENSC, CMMB, BCAB, and PASG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	1.96	N/A	N/A	($0.29) per share	-1.27
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
ENSC Ensysce Biosciences	$5.21M	1.17	N/A	N/A	$1.03 per share	1.99
PASG Passage Bio	N/A	N/A	N/A	N/A	$12.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	N/A
CMMB Chemomab Therapeutics	-$13.94M	-$0.76	N/A	N/A	N/A	N/A	-88.15%	-70.00%	8/20/2025 (Estimated)
ENSC Ensysce Biosciences	-$7.99M	-$6.54	N/A	N/A	N/A	-88.76%	-167.23%	-104.59%	N/A
PASG Passage Bio	-$64.77M	-$20.40	N/A	N/A	N/A	N/A	-103.87%	-59.95%	N/A

Latest ENSC, CMMB, BCAB, and PASG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/13/2025	Q2 2025	ENSC Ensysce Biosciences	-$1.02	-$0.79	+$0.23	-$0.79	$0.67 million	$1.37 million
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	1.24	1.24
CMMB Chemomab Therapeutics	N/A	5.33	5.33
ENSC Ensysce Biosciences	N/A	2.10	2.50
PASG Passage Bio	N/A	3.05	3.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
CMMB Chemomab Therapeutics	46.05%
ENSC Ensysce Biosciences	5.63%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.22%
CMMB Chemomab Therapeutics	11.91%
ENSC Ensysce Biosciences	7.90%
PASG Passage Bio	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.72 million	51.86 million	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
ENSC Ensysce Biosciences	10	2.97 million	2.18 million	Not Optionable
PASG Passage Bio	130	3.18 million	3.02 million	Optionable

ENSC, CMMB, BCAB, and PASG Headlines

Recent News About These Companies

Wedbush Comments on Passage Bio's Q3 Earnings (NASDAQ:PASG)

4 hours ago | americanbankingnews.com

Passage Bio (PASG) Receives a Buy from TD Cowen

August 15 at 9:03 PM | theglobeandmail.com

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

August 15 at 10:55 AM | zacks.com

Canaccord Genuity Group Lowers Passage Bio (NASDAQ:PASG) Price Target to $67.00

August 15 at 4:03 AM | americanbankingnews.com

Wedbush Issues Positive Forecast for Passage Bio (NASDAQ:PASG) Stock Price

August 15 at 3:09 AM | americanbankingnews.com

Passage Bio price target lowered to $67 from $260 at Canaccord

August 14 at 11:34 PM | msn.com

Passage Bio Reports Q2 2025 Progress and Financials

August 13 at 7:34 AM | msn.com

Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year

August 12, 2025 | msn.com

Passage Bio Reports Promising Q2 2025 Financial Results

August 12, 2025 | msn.com

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

August 12, 2025 | globenewswire.com

Passage Bio (PASG) Projected to Post Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

Passage Bio Regains Nasdaq Compliance with Stock Price

July 29, 2025 | tipranks.com

Insider Buying: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Acquires 13,123 Shares of Stock

July 25, 2025 | insidertrades.com

Passage Bio Announces 1-for-20 Reverse Stock Split

July 10, 2025 | globenewswire.com

Passage Bio, Inc. (PASG) Income Statement - Yahoo Finance

July 1, 2025 | finance.yahoo.com

PASG Passage Bio, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 Shares

June 27, 2025 | insidertrades.com

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

June 23, 2025 | globenewswire.com

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025 | msn.com

Passage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestre

May 13, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC, CMMB, BCAB, and PASG Company Descriptions

BioAtla NASDAQ:BCAB

$0.37 +0.00 (+0.99%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+2.26%)

As of 08/15/2025 07:55 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Chemomab Therapeutics NASDAQ:CMMB

$0.93 +0.03 (+3.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.02 (+2.15%)

As of 08/15/2025 07:59 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Ensysce Biosciences NASDAQ:ENSC

$2.05 -0.01 (-0.49%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.10 +0.05 (+2.24%)

As of 08/15/2025 07:50 PM Eastern

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Passage Bio NASDAQ:PASG

$6.95 -0.64 (-8.43%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$7.00 +0.04 (+0.65%)

As of 08/15/2025 07:53 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time